AUSTIN, Texas, Oct. 24, 2018 /PRNewswire/ -- It doesn't take a germaphobe to know bacteria is everywhere, and scientists around the globe are constantly working toward a healthier tomorrow.
Enter, SelenBio, Inc.™️, a Texas-based biotechnology company, specializing in the prevention of bacterial biofilm formation for dental, healthcare, industrial and consumer applications.
In January, the company launched their first product, DenteShield™️, which inhibits bacteria colonization responsible for plaque, decay, white spot lesions and gingival inflammation. FDA-approved, the product is available through dental professionals and national distributor Patterson Dental; as well as a regional distributor Midwest Dental, serving both Texas and Oklahoma.
So how does it work?
"Selenium," said SelenBio Co-Founder and Chief Science Officer Ted Reid, Ph.D. "I've studied this element for more than 30 years. Pure and simple, this element is common in the body and when incorporated into an organic molecule, it can take an electron from sulfur and give it to oxygen, generating superoxide. It is this 'superoxide radical' that kills bacteria on contact."
Not only does it kill bacteria on contact, Reid explained, but it kills specifically where necessary, and since this is a catalytic mechanism, it just keeps on going – like an "energizer bunny."
Additionally, selenium is inexpensive. In years' past, silver and copper have been used in similar ways to kill bacteria – but the cost is much more, and the specificity is not nearly the same as that of selenium. SelenBio™️ trademarked the selenium product as SELDOX™️ and have since launched their first dental product DenteShield™️ with great success. But this is only the beginning.
"Our case studies have proven this will work well with periodontal disease in animals," said Kenny Gallagher, SelenBio CEO. "So many dogs, for example, have periodontal issues that require multiple teeth to be pulled. We've already proven that our next venture – GingiShield™️ - will be a huge help for animals with oral bacterial colonization."
Gallagher explained with the onset of antibiotic-resistant strands of disease in recent years, there's never been a better time to develop a platform for antimicrobial technology – looking far beyond dental issues and into the entire healthcare arena.
"We have the technology to revolutionize the antibacterial industry," Gallagher said. "Our intention is to focus on all primary causes of bacterial problems and hit them head on."
Beyond the dental industry, Gallagher said, SelenBio already is working on wound care and catheters, specifically.
CONTACT: Kim Davis, (806) 544-4255
SOURCE SelenBio, Inc.